Koohpayeh Seyedeh Atefeh, Hosseini Meimanat, Nasiri Morteza, Rezaei Masoud
Student Research Committee, Department of Community Health Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Community Health Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Educ Health Promot. 2021 Jul 30;10:272. doi: 10.4103/jehp.jehp_18_21. eCollection 2021.
Recent studies have reported inconclusive results regarding the therapeutic effects of Rosa damascena on the outcomes of primary dysmenorrhea (PD) and premenstrual syndrome (PMS). Hence, this study is aimed to summarize the findings of randomized controlled trials (RCTs) regarding the effects of this treatment on menstruation-related pain as the primary outcome and menstruation-related headache, fatigue, anxiety, and bloating as the secondary outcomes. This study evaluated parallel-group and cross-over RCTs on aromatherapy, topical treatment, or oral intake of R. damascena products for the treatment groups versus placebo, nontreated, or conventional treatment groups. Seven electronic databases (Web of Science Core Collection, Scopus, Embase, CENTRAL, CINAHL, SID, and MagIran) and one search engine (PubMed) were searched from inception to January 15, 2021. Of 1468 trials found in the initial search, 983 potentially relevant articles were screened by title and abstract. After examining the full-text of 13 studies for compliance with the inclusion criteria, seven studies were considered eligible for this review. A random-effects model was used to pool the data; otherwise, a narrative summary was presented. The retrieved studies were conducted on females with PD or PMS, aged 18-35 years. The total sample size of the intervention and comparator arms was 276 and 272. The results showed that R. damascena had a nonsignificant alleviating effect on the menstruation-related pain (weighted mean difference [WMD]: -0.47; 95% confidence interval [CI]: -1.25, 0.31; = 0.234). Such findings were also found for menstruation-related anxiety (WMD: -0.40; 95% CI: -0.91, 0.11; = 0.125). However, the treatment significantly reduced the menstruation-related headache (WMD: -0.42; 95% CI: -0.74, -0.11; = 0.008), fatigue (WMD: -0.48; 95% CI: -0.87, -0.09; = 0.015), and bloating (WMD: -0.72; 95% CI: -1.21, -0.22; = 0.005). Since R. damascena had no significant effects on menstruation-related pain and anxiety, further studies with improved methodological quality are suggested to evaluate the effects of the treatment on these symptoms, using different dosages and durations.
近期研究报告了大马士革玫瑰对原发性痛经（PD）和经前综合征（PMS）结局的治疗效果尚无定论。因此，本研究旨在总结随机对照试验（RCT）的结果，这些试验以这种治疗对与月经相关的疼痛作为主要结局，以及对与月经相关的头痛、疲劳、焦虑和腹胀作为次要结局的影响。本研究评估了治疗组采用芳香疗法、局部治疗或口服大马士革玫瑰产品的平行组和交叉RCT，与安慰剂组、未治疗组或传统治疗组进行对比。检索了七个电子数据库（科学引文索引核心合集、Scopus、Embase、CENTRAL、护理学与健康领域数据库、伊朗科学信息数据库和伊朗医学数据库）以及一个搜索引擎（PubMed），检索时间从建库至2021年1月15日。在初步检索中找到的1468项试验中，通过标题和摘要筛选出983篇可能相关的文章。在审查了13项研究的全文是否符合纳入标准后，7项研究被认为符合本综述的条件。采用随机效应模型合并数据；否则，进行叙述性总结。检索到的研究针对年龄在18 - 35岁的患有PD或PMS的女性进行。干预组和对照组的总样本量分别为276和272。结果表明，大马士革玫瑰对与月经相关的疼痛缓解作用不显著（加权平均差[WMD]：-0.47；95%置信区间[CI]：-1.25，0.31；P = 0.234）。在与月经相关的焦虑方面也有类似发现（WMD：-0.40；95% CI：-0.91，0.11；P = 0.125）。然而，该治疗显著减轻了与月经相关的头痛（WMD：-0.42；95% CI：-0.74，-0.11；P = （此处原文有误，推测应为P = 0.008））、疲劳（WMD：-0.48；95% CI：-0.87，-0.09；P = 0.015）和腹胀（WMD：-0.72；95% CI：-1.21，-0.22；P = 0.005）。由于大马士革玫瑰对与月经相关的疼痛和焦虑没有显著影响，建议进一步开展方法学质量更高的研究，使用不同剂量和疗程来评估该治疗对这些症状的影响。
